Skip to main content
Apyx Medical Corp logo

Apyx Medical Corp — Investor Relations & Filings

Ticker · APYX ISIN · US0323472052 LEI · 5299009QZVYUYO082S45 US Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2016-07-11 Major Shareholding Noti…
Country US United States of America
Listing US APYX

About Apyx Medical Corp

https://apyxmedical.com/

Apyx Medical Corporation is an advanced energy technology company that develops, manufactures, and markets innovative products for surgical and cosmetic markets. The company's proprietary Helium Plasma Platform, which is the foundation for its Renuvion® and J-Plasma® brands, utilizes a unique combination of helium plasma and radiofrequency (RF) energy. These systems are designed to deliver controlled energy for the cutting, coagulation, and ablation of soft tissue, with a primary focus on aesthetic procedures for skin tightening and body contouring. Apyx Medical, formerly Bovie Medical, leverages its expertise in energy-based waveforms to provide transformative solutions for surgeons and their patients.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2016-07-11 English
BOVIE 8-K RE: LOAN AMENDMENT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 28, 2016, reporting a loan amendment transaction. It details the amendment of loan terms including maturity dates and collateral release. The document includes a summary of the amended loan agreement and references exhibits related to the loan amendment. There are no financial statements or comprehensive financial data presented, only a description of a financing event. This fits the category of a Capital/Financing Update, as it reports on changes to the company's financing arrangements rather than a full financial report or other types of filings.
2016-07-05 English
DEF 14A
Proxy Solicitation & Information Statement
2016-06-10 English
BOVIE MEDICAL CORPORATION SD 12-31-2015
Regulatory Filings Classification · 95% confidence The document is a Form SD filed with the SEC, which is a Specialized Disclosure Report related to conflict minerals compliance under Rule 13p-1 of the Securities Exchange Act. It discloses the company's inquiry and findings regarding the origin of conflict minerals used in its products for the calendar year 2015. The document is not a full annual report, audit report, or financial statement, but a specific regulatory disclosure report. The length is 4328 characters, which is relatively short but contains the full disclosure text, not just an announcement. Therefore, it fits the category of Regulatory Filings (RNS) as a specialized disclosure report that does not fit other specific categories.
2016-05-24 English
FORM 10-Q
Interim / Quarterly Report Q1 2016
2016-05-11 English
BOVIE 8-K RE FIRST QUARTER RESULTS
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2016, reporting the company's results of operations for the first quarter ending March 31, 2016. It references a press release attached as Exhibit 99.1 that contains the financial results. The document itself is short (2821 characters) and primarily serves as a current report announcing the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2016-05-11 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.